Nicolas Musi

EBioMedicine · 2019

⊕ Open access · CC-BY

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

▲ 1,208

EBioMedicine · 2023

⊕ Open access · OA

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

▲ 269

Nature Medicine · 2023

⊕ Preprint · OA

Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial

▲ 261

The Journal of Prevention of Alzheimer s Disease · 2021

⊕ Open access · OA

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial

▲ 192

EBioMedicine · 2022

⊕ Open access · OA

Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans

▲ 91

Current Molecular Biology Reports · 2021

⊕ Open access · OA

Cellular Senescence in Idiopathic Pulmonary Fibrosis

▲ 68

Journal of the American Geriatrics Society · 2021

⊕ Open access · CC-BY

Fisetin for <scp>COVID</scp> ‐19 in skilled nursing facilities: Senolytic trials in the <scp>COVID</scp> era

▲ 50

GeroScience · 2023

⊕ Preprint · OA

A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

▲ 41

Endocrine Reviews · 2023

⊕ Open access · OA

Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns

▲ 40

Research Square · 2023

⊕ Preprint · CC-BY

Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease

▲ 37

Cell Reports · 2023

⊕ Open access · CC-BY

Skeletal muscle TFEB signaling promotes central nervous system function and reduces neuroinflammation during aging and neurodegenerative disease

▲ 36

The Journals of Gerontology Series A · 2023

⊕ Open access · CC0

Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop

▲ 28

Aging Cell · 2020

⊕ Open access · CC-BY

Acarbose improved survival for <i>Apc^+/Min</i> mice

▲ 26

Cell Metabolism · 2025

⊕ Preprint · OA

Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice

▲ 13

Neurotherapeutics · 2025

⊕ Open access · CC-BY

Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease

▲ 13

Alzheimer s & Dementia · 2020

⊕ Open access · OA

A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes

▲ 10

Research Square · 2024

⊕ Preprint · CC-BY

Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease

▲ 8